Drugs / DTGM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00074750 | Dec 2003 → Dec 2004 | acute myeloid leukemia, chronic myelomonocytic leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTGM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00074750 ↗ |
| Action | Deplete | “It then attaches to the cells and allows the toxin to enter the leukemic cells and destroy them.” NCT00074750 ↗ |
| Modality | Protein / enzyme biologic | “Starting dose of DTGM fusion protein 2 mcg/kg/day as a short (30 min) intravenous infusion” NCT00074750 ↗ |
| Route | Intravenous | “intravenous infusion” NCT00074750 ↗ |